SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accounts Receivable of $23.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $29.47M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$5.62M, a 257.70% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $16.42M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $7.13M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $22.30M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$2.08M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$18.77M, a 214.66% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $16.37M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $29.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $23.86M 10-Q · filed 2026-08-03 | $40.27M derived: sum of 3 quarters · filed 2026-08-03 | $47.41M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | -$5.62M 10-Q · filed 2026-05-05 | $10.80M derived: sum of 2 quarters · filed 2026-05-05 | $17.93M derived: sum of 3 quarters · filed 2026-05-05 | $13.12M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $16.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $23.55M derived: sum of 2 quarters · filed 2026-03-02 | $18.74M derived: sum of 3 quarters · filed 2026-08-03 | $22.30M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $7.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2026-08-03 | $5.88M 10-Q · filed 2025-11-06 | $2.55M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | -$4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$1.25M 10-Q · filed 2026-08-03 | -$4.58M derived: sum of 3 quarters · filed 2026-08-03 | -$11.66M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $3.56M 10-Q · filed 2026-05-05 | $232.00K derived: sum of 2 quarters · filed 2026-05-05 | -$6.85M derived: sum of 3 quarters · filed 2026-05-05 | -$2.09M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$10.42M derived: sum of 2 quarters · filed 2026-03-02 | -$5.66M derived: sum of 3 quarters · filed 2026-03-02 | -$2.08M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.33M derived: sum of 2 quarters · filed 2025-11-06 | $1.25M 10-Q · filed 2025-11-06 | $3.64M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $8.34M 10-Q · filed 2025-08-05 | $10.73M derived: sum of 3 quarters · filed 2026-03-02 | $15.94M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $3.58M 10-Q · filed 2025-05-06 | $5.97M derived: sum of 2 quarters · filed 2026-03-02 | $11.18M derived: sum of 3 quarters · filed 2026-03-02 | $6.79M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $7.60M derived: sum of 2 quarters · filed 2026-03-02 | $3.21M derived: sum of 3 quarters · filed 2026-03-02 | -$18.77M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $816.00K derived: sum of 2 quarters · filed 2024-11-04 | -$21.16M 10-Q · filed 2024-11-04 | -$19.75M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | -$4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$26.36M 10-Q · filed 2024-08-06 | -$24.96M derived: sum of 3 quarters · filed 2025-02-25 | -$19.09M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | -$21.97M 10-Q · filed 2024-05-08 | -$20.56M derived: sum of 2 quarters · filed 2025-02-25 | -$14.70M derived: sum of 3 quarters · filed 2025-02-25 | -$1.79M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.27M derived: sum of 2 quarters · filed 2025-02-25 | $20.18M derived: sum of 3 quarters · filed 2025-02-25 | $16.37M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $5.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $18.77M derived: sum of 2 quarters · filed 2023-11-08 | $14.96M 10-Q · filed 2023-11-08 | $18.44M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.09M 10-Q · filed 2023-08-08 | $12.58M derived: sum of 3 quarters · filed 2023-08-08 | $8.83M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$3.81M 10-Q · filed 2023-05-09 | -$327.00K derived: sum of 2 quarters · filed 2023-05-09 | -$4.07M derived: sum of 3 quarters · filed 2023-05-09 | $6.13M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$262.00K derived: sum of 2 quarters · filed 2023-03-09 | $9.94M derived: sum of 3 quarters · filed 2023-03-09 | -$3.87M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.45M derived: sum of 2 quarters · filed 2022-11-09 | -$7.35M 10-Q · filed 2022-11-09 | $415.00K derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-06-30 | $10.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$3.60M 10-Q · filed 2022-08-08 | $4.16M derived: sum of 3 quarters · filed 2023-03-09 | $10.57M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-03-31 | -$13.80M 10-Q · filed 2022-05-12 | -$6.04M derived: sum of 2 quarters · filed 2023-03-09 | $371.00K derived: sum of 3 quarters · filed 2023-03-09 | -$11.02M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2020-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $14.18M derived: sum of 2 quarters · filed 2023-03-09 | $2.78M derived: sum of 3 quarters · filed 2023-03-09 | $34.61M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $6.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$4.98M derived: sum of 2 quarters · filed 2021-11-05 | $26.84M 10-Q · filed 2021-11-05 | $27.43M derived: sum of 4 quarters · filed 2022-04-13 | |
| 2020-06-30 | -$11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $20.43M 10-Q · filed 2021-08-06 | $21.02M derived: sum of 3 quarters · filed 2022-04-13 | $23.12M derived: sum of 4 quarters · filed 2022-04-13 | |
| 2020-03-31 | $31.82M 10-Q · filed 2021-05-07 | $32.42M derived: sum of 2 quarters · filed 2022-04-13 | $34.51M derived: sum of 3 quarters · filed 2022-04-13 | $39.09M derived: sum of 4 quarters · filed 2022-04-13 | |
| 2019-12-31 | $593.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $2.69M derived: sum of 2 quarters · filed 2022-04-13 | $7.26M derived: sum of 3 quarters · filed 2022-04-13 | -$15.75M 10-K · filed 2022-04-13 | |
| 2019-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $6.67M derived: sum of 2 quarters · filed 2020-11-06 | -$16.34M 10-Q · filed 2020-11-06 | $8.82M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2019-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | -$18.44M 10-Q · filed 2020-08-17 | $6.73M derived: sum of 3 quarters · filed 2021-03-08 | $9.64M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2019-03-31 | -$23.01M 10-Q · filed 2020-05-15 | $2.16M derived: sum of 2 quarters · filed 2021-03-08 | $5.07M derived: sum of 3 quarters · filed 2021-03-08 | $12.04M derived: sum of 4 quarters · filed 2021-03-08 | |
| 2018-12-31 | $25.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $28.08M derived: sum of 2 quarters · filed 2021-03-08 | $35.06M derived: sum of 3 quarters · filed 2021-03-08 | $35.86M 10-K · filed 2021-03-08 | |
| 2018-09-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $9.89M derived: sum of 2 quarters · filed 2019-11-08 | $10.69M 10-Q · filed 2019-11-08 | $20.11M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $7.78M 10-Q · filed 2019-08-09 | $17.20M derived: sum of 3 quarters · filed 2020-02-28 | $22.20M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $798.00K 10-Q · filed 2019-05-10 | $10.22M derived: sum of 2 quarters · filed 2020-02-28 | $15.23M derived: sum of 3 quarters · filed 2020-02-28 | $27.50M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $14.43M derived: sum of 2 quarters · filed 2020-02-28 | $26.70M derived: sum of 3 quarters · filed 2020-02-28 | $24.06M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $17.28M derived: sum of 2 quarters · filed 2018-11-09 | $14.64M 10-Q · filed 2018-11-09 | $19.95M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $12.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $9.63M 10-Q · filed 2018-08-09 | $14.94M derived: sum of 3 quarters · filed 2019-03-01 | $16.88M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | -$2.64M 10-Q · filed 2018-05-10 | -$2.64M 10-Q · filed 2017-05-09 | $2.66M derived: sum of 2 quarters · filed 2019-03-01 | $4.60M derived: sum of 3 quarters · filed 2019-03-01 | $8.23M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $7.25M derived: sum of 2 quarters · filed 2019-03-01 | $10.88M derived: sum of 3 quarters · filed 2019-03-01 | $15.62M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $5.57M derived: sum of 2 quarters · filed 2017-11-09 | $10.31M 10-Q · filed 2017-11-09 | $12.62M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $8.37M 10-Q · filed 2017-08-03 | $10.68M derived: sum of 3 quarters · filed 2018-03-01 | $16.38M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $4.74M 10-Q · filed 2017-05-09 | $7.05M derived: sum of 2 quarters · filed 2018-03-01 | $12.75M derived: sum of 3 quarters · filed 2018-03-01 | $11.38M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $2.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $8.01M derived: sum of 2 quarters · filed 2018-03-01 | $6.64M derived: sum of 3 quarters · filed 2018-03-01 | $8.64M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $5.70M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $4.33M derived: sum of 2 quarters · filed 2017-01-23 | $6.33M 10-Q/A · filed 2017-01-20 | $8.30M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$1.37M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | $630.00K 10-Q/A · filed 2017-01-23 | $2.60M derived: sum of 3 quarters · filed 2017-03-16 | $7.05M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $2.00M 10-Q/A · filed 2017-01-20 | $3.97M derived: sum of 2 quarters · filed 2017-03-16 | $8.42M derived: sum of 3 quarters · filed 2017-03-16 | $9.55M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $1.97M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $6.42M derived: sum of 2 quarters · filed 2017-03-16 | $7.54M derived: sum of 3 quarters · filed 2017-03-16 | $12.22M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $4.45M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $5.58M derived: sum of 2 quarters · filed 2017-01-20 | $10.25M 10-Q/A · filed 2017-01-20 | $8.08M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2014-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $5.80M 10-Q · filed 2015-08-07 | $3.63M derived: sum of 3 quarters · filed 2017-01-20 | $10.31M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2014-03-31 | $4.67M 10-Q · filed 2015-05-06 | $2.51M derived: sum of 2 quarters · filed 2017-01-20 | $9.18M derived: sum of 3 quarters · filed 2017-01-20 | $8.06M derived: sum of 4 quarters · filed 2017-01-20 | |
| 2013-12-31 | -$2.17M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $4.51M derived: sum of 2 quarters · filed 2017-01-20 | $3.39M derived: sum of 3 quarters · filed 2017-01-20 | $5.04M 10-K/A · filed 2017-01-20 | |
| 2013-09-30 | $6.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $5.56M derived: sum of 2 quarters · filed 2014-11-12 | $7.21M 10-Q · filed 2014-11-12 | $6.85M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $537.00K 10-Q · filed 2014-08-12 | $176.00K derived: sum of 3 quarters · filed 2015-03-12 | ||
| 2013-03-31 | $1.65M 10-Q · filed 2014-05-13 | $1.29M derived: sum of 2 quarters · filed 2015-03-12 | |||
| 2012-12-31 | -$361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $11.00K 10-K · filed 2015-03-12 | |||
| 2012-09-30 | $372.00K 10-Q · filed 2013-11-13 | ||||
| 2011-12-31 | -$560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$44.00K 10-K · filed 2014-03-21 | |||
| 2011-09-30 | $516.00K 10-Q · filed 2012-11-02 | ||||
| 2010-12-31 | -$284.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |